Zealand Pharma Presents Phase 2 Petrelintide Data Ahead of Planned Phase 3 Launch in H2 2026

With Phase 3 chronic weight management trials scheduled to begin in the second half of 2026, Zealand Pharma's latest ZUPREME-1 readout places petrelintide, a once-weekly subcutaneous amylin analog, on a manufacturing and supply-chain trajectory that warrants early attention from plant heads and CMC leads.

Presented at the American Diabetes Association 2026 Scientific Sessions in New Orleans, the 42-week Phase 2 data from 485 randomized adults showed petrelintide achieving mean body weight reductions of up to 10.7% from baseline versus 1.7% for placebo (efficacy estimand; p<0.001). The trial met its primary endpoint at Week 28 across all five dose arms. Between 88% and 98% of participants successfully escalated to their targeted maintenance dose, a dose-escalation completion rate that carries direct implications for formulation stability and device reliability at commercial scale.

Tolerability data will shape the commercial profile as much as efficacy. Nausea was the most common gastrointestinal adverse event, reported in 19.6% of petrelintide participants versus 6.2% on placebo; vomiting was rare at 3.0% versus 6.2% for placebo. Critically, only 1.5% of participants discontinued due to GI adverse events, a discontinuation rate that, if sustained in Phase 3, would distinguish petrelintide from the tolerability burden associated with GLP-1 receptor agonists and reduce the attrition-driven demand variability that complicated early semaglutide supply planning.

For QA directors and regulatory leads, the cardiometabolic secondary endpoints add complexity to the Phase 3 protocol scope. Petrelintide was associated with waist circumference reductions of 7.9–10.8 cm, alongside reductions in high-sensitivity C-reactive protein and triglycerides. Capturing these endpoints under 21 CFR Part 211-compliant analytical frameworks and aligning them with ICH Q10 pharmaceutical quality system requirements will be a non-trivial exercise as Zealand moves into pivotal studies.

The amylin analog mechanism also introduces fill-finish and cold-chain considerations distinct from the GLP-1 class. Once-weekly subcutaneous delivery at multiple dose strengths, five arms were evaluated in ZUPREME-1, implies a device and formulation portfolio that must be validated across the full dose range before Phase 3 initiation. Supply organisations that tracked the fill-finish bottlenecks experienced during the GLP-1 ramp-up have a narrow window to assess whether analogous constraints apply to peptide-based amylin analogs at the volumes a successful Phase 3 would require.

The initiation of Phase 3 in H2 2026 will serve as the first measurable checkpoint for whether Zealand's manufacturing and regulatory infrastructure can support the scale demands that pivotal chronic weight management trials impose.

Source: Zealand Pharma A/S via GlobeNewswire, 5 June 2026.